Is SR-47436 Safe in Breastfeeding

I am a breastfeeding mother and i want to know if it is safe to use SR-47436? Is SR-47436 safe for nursing mother and child? Does SR-47436 extracts into breast milk? Does SR-47436 has any long term or short term side effects on infants? Can SR-47436 influence milk supply or can SR-47436 decrease milk supply in lactating mothers?

• DrLact safety Score for SR-47436 is 5 out of 8 which is considered Unsafe as per our analyses.
• A safety Score of 5 indicates that usage of SR-47436 may cause serious side effects in breastfed baby.
• Our study of different scientific research indicates that SR-47436 may cause moderate to high side effects or may affect milk supply in lactating mother.
• Our suggestion is to use safer alternate options rather than using SR-47436 .
• It is recommended to evaluate the advantage of not breastfeeding while using SR-47436 Vs not using SR-47436 And continue breastfeeding.
• While using SR-47436 Its must to monitor child for possible reactions. It is also important to understand that side effects vary largely based on age of breastfed child and time of medication in addition to dosage.
• Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.

At latest update, relevant published data on excretion into breast milk were not found. Because of a high protein-binding capacity, a significant excretion into breast milk is unlikely. However, it is one among the Sartan drugs (ARA-II type) with the longest half-life and highest oral bioavailability. The latter properties make it less convenient for use while breastfeeding. Reportedly, a newborn infant appeared with transient renal failure (kidney malfunction) whose mother had taken this medication during pregnancy. Until more data on this medication is available safer alternative drugs are preferred especially in premature babies or during the neonatal period. Should an ARA-II medication (Sartan type) be necessary, the associated risk may be decreased by choosing the one with a favorable pharmacokinetics (shorter half-life elimination time and lower bioavailability) like Eprosartan and Losartan.

Because no information is available on the use of SR-47436 during breastfeeding, an alternate drug may be preferred, especially while nursing a newborn or preterm infant.